RFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.

Abstract

Recurrent bleeding in severe haemophilia B causes painful hemarthroses and reduces capacity for physical activity. Recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis results in low annualised bleeding rates, with the potential to improve patients' health-related quality of life (HRQoL). To present a post hoc analysis of data from B-LONG describing change over time in patient-reported outcomes associated with pain and physical activity. Patients (≥12 years) who received weekly dose-adjusted or interval-adjusted rFIXFc prophylaxis and completed the Haemophilia-Specific QoL questionnaire for adolescents (Haemo-QoL) or adults (Haem-A-QoL) at baseline (BL) and end of study (EoS). Individual level changes in items of the 'Physical Health' and 'Sports and Leisure' domains, categorised as 'never/rarely/seldom' or 'sometimes/often/all the time', were analysed using McNemar's test to compare distribution of responses at EoS versus BL. At EoS versus BL, a significantly greater proportion of patients did not experience painful swellings (64%vs. 44%; P=.004), painful joints (44%vs. 28%; P=.003) or pain when moving (54%vs. 41%; P=.026). Additionally, at EoS versus BL, patients were less likely to avoid participating in sports like football (30%vs. 8%; P=.002), avoid sports due to their haemophilia (47%vs. 27%; P=.007), or experience difficulty walking as far as they wanted (63%vs. 43%; P=.001). The proportion of patients who played sports as much as the general population was numerically increased (52%vs. 37%; P=.033) at EoS versus BL. Results of the analysis suggest that over time, rFIXFc prophylaxis is associated with significant improvements in pain and physical functioning. This contributes to previous evidence of overall HRQoL improvements in patients with haemophilia B treated with rFIXFc.